Jeffrey Stuart Peters - Mar 6, 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Mar 6, 2024
Transactions value $
-$421,938
Form type
4
Date filed
3/8/2024, 04:14 PM
Previous filing
Feb 28, 2024
Next filing
Apr 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $125K +10.9K +122.26% $11.50 19.8K Mar 6, 2024 Direct
transaction MGNX Common Stock Options Exercise $88.8K +8.75K +44.26% $10.15 28.5K Mar 6, 2024 Direct
transaction MGNX Common Stock Sale -$422K -19.6K -68.81% $21.50 8.9K Mar 6, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise -$125K -10.9K -100% $11.50 0 Mar 6, 2024 Common Stock 10.9K $11.50 Direct F2
transaction MGNX Employee stock option (right to buy) Options Exercise -$88.8K -8.75K -18.18% $10.15 39.4K Mar 6, 2024 Common Stock 8.75K $10.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
F2 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.